

Anthony Stein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3250660/publications.pdf>

Version: 2024-02-01

40
papers

2,136
citations

567281

15
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

3175
citing authors

#	ARTICLE	IF	CITATIONS
1	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
2	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. <i>Bone Marrow Transplantation</i> , 2022, 57, 830-833.	2.4	2
3	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226.	1.3	2
4	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	6
5	Venetoclax-containing regimens in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072098664.	2.5	22
6	Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. <i>American Journal of Hematology</i> , 2021, 96, E140-E143.	4.1	1
7	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	1.2	6
8	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA+Ven) or liposomal daunorubicin+cytarabine (CPX+351). <i>American Journal of Hematology</i> , 2021, 96, E196-E200.	4.1	10
9	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470.	2.4	8
10	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	6.2	2
11	First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 671-683.	0.8	8
12	Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion. <i>Haematologica</i> , 2021, 106, 1484-1488.	3.5	9
13	Current and Emerging Therapies for Acute Myeloid Leukemia. <i>Cancer Treatment and Research</i> , 2021, 181, 57-73.	0.5	2
14	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
15	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13
16	CD33 directed bispecific antibodies in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101224.	1.7	17
17	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1425-1432.	2.0	5
18	Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2665-2673.	1.3	44

#	ARTICLE	IF	CITATIONS
19	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
20	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	5.7	135
21	A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 1052-1062.	1.3	3
22	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019, 87, 106230.	0.8	9
23	Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1025-1033.	0.8	41
24	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.4	12
25	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	2.6	36
26	High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine. <i>Blood</i> , 2019, 134, 2706-2706.	1.4	10
27	Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 4254-4254.	1.4	17
28	Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 4107-4107.	1.4	23
29	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019, 134, 4518-4518.	1.4	1
30	Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 301-307.	2.0	35
31	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835.	2.0	15
32	First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. <i>Journal of Hematology and Oncology</i> , 2018, 11, 61.	17.0	37
33	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 618-624.	2.0	84
34	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	27.0	1,443
35	Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. <i>Journal of Medical Economics</i> , 2017, 20, 911-922.	2.1	21
36	Extramedullary Relapse Following Total Marrow and Lymphoid Irradiation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 75-81.	0.8	30

#	ARTICLE	IF	CITATIONS
37	Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. Blood, 2009, 114, 2771-2771.	1.4	2
38	90.y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).. Blood, 2009, 114, 3357-3357.	1.4	0
39	Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.. Blood, 2007, 110, 3021-3021.	1.4	0
40	Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in "High Risk" B-Cell Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 3500-3500.	1.4	0